Background: To assess the impacts of age, performance status, and clinical stage on advanced urothelial carcinoma of the bladder (UCB) in patients treated with different treatment modalities. Methods: This retrospective study included 160 patients who underwent radical cystectomy (RC) with/without neoadjuvant or adjuvant chemoradiotherapy, palliative chemotherapy/radiotherapy/chemoradiotherapy (CRT), and transurethral resection of bladder tumor (TURBT) monotherapy for advanced UCB in one institution from 2000 to 2010. KaplaneMeier analysis was used to calculate the survival distributions of overall survival (OS). The quality of life of the patients was also analyzed. Results: The median age of the patients was 74.0 years, and the mean survival interval was 31.5 months. The 2-year OS was significantly different among the three modalities [RC > TURBT monotherapy, odds ratio (OR): 1.86, 95% CI: 1.17e2.96, p ¼ 0.009; CRT > TURBT monotherapy, OR: 1.65, 95% CI: 1.06e2.57, p ¼ 0.026]. There were no significant differences in the 5-and 10-year OS rates between the three treatment modalities. Those younger than 76 years receiving RC had a significantly better 2-year OS than those undergoing CRT and TURBT monotherapy (RC > TURBT monotherapy, OR: 2.38; 95% CI: 1.30e4.33, p ¼ 0.005). The number and duration of re-hospitalizations were highest in the CRT group and lowest in the TURBT group. Conclusion: The short-and long-term OS rates of the three modalities were similar in those older than 76 years. Therefore, patients younger than age 76 years are likely to have a better outcome undergoing radical cystectomy for advanced UCB.
Introduction
Bladder cancer is the second most prevalent malignancy of the genitourinary tract, with an estimated 73,510 new cases and 14,880 deaths in the United States in 2012, 1 and 2003 new cases and 807 deaths in Taiwan in 2012. 2 Typically, the risks of bladder cancer increase with age, with an average age at diagnosis of 65 years. 3 Among patients with urothelial carcinoma of the bladder (UCB), 20e40% will present with, or will develop, muscle-invasive disease. 4 Radical cystectomy (RC) for advanced UCB is the gold standard for local control and increased survival in patients with muscle-invasive tumors. 5 Elderly patients with advanced UCB may be ineligible for radical surgery due to comorbid conditions, limited Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.
physiological reserve, or a higher underlying risk of developing complications. 6 Even though advances in surgical techniques have improved perioperative care and made RC feasible in elderly patients, 7, 8 they may be denied radical surgery due to their age alone. 9, 10 Advanced age is associated with poorer outcomes in patients treated with radical cystectomy. Nielsen et al 3 reviewed the records of 888 patients with advanced UCB who underwent radical cystectomy and pelvic lymph node dissection in three institutions for localized disease, finding advanced age to be independently and significantly associated with more pathologically advanced disease and poorer bladder-specific mortality after the surgery. In a previous report of Goffin et al, 11 bladder-sparing radiotherapy with concurrent chemotherapy was shown to be feasible in patients aged 70 years or over with a good performance status, although this was not entirely complication-free.
The management of advanced UCB in elderly patients is an important, controversial, and challenging problem. The goal of this retrospective study was to compare the overall survival (OS) and the quality of life of elderly patients receiving three different treatment modalities for advanced UCB in Taiwan.
Methods
This retrospective study was conducted using the Comprehensive Tri-Service General Hospital Urologic Oncology database after approval by the hospital's Institutional Review Board. The study population consisted of 160 consecutive patients diagnosed with advanced UCB between January 2000 and December 2010 at the Tri-Service General Hospital, Taipei, Taiwan. Patients who had a histological diagnosis other than urothelial carcinoma were excluded from the study, and those with clinical stage T2-T4N0-N2M0-M1 UCB, based on pathological specimens, were included. The TNM classification for UCB was used according to the 7 th edition of the American Joint Committee on Cancer/Union International Cancer TNM classification.
Three treatment modalities were used for all 160 patients, including radical cystectomy (RC) with/without neoadjuvant or adjuvant chemotherapy, palliative chemotherapy, radiotherapy, or chemoradiotherapy (CRT), and transurethral resection of bladder tumor (TURBT) monotherapy.
In order to validate the associations between different treatment modalities and OS in a larger population, we took data from the Longitudinal Health Insurance Database (LHID2000) of Taiwan. The LHID2000 includes all the original claims data and registration files for 1,000,000 individuals randomly sampled from the 2000 Registry for Beneficiaries (n ¼ 23. We assigned the first bladder cancer diagnosis as the index date. In order to increase the validity of the advanced bladder cancer diagnosis, we only included advanced bladder cancer cases that consisted of at least two bladder cancer diagnoses, with receipt of TURBT procedures at least three times (ICD-9-CM codes 57.4 and 57.49). A total of 699 cases were matched of advanced bladder cancer who received three different treatment modalities, including 201 patients with RC (ICD-9-CM codes 57.7, 57.71, and 57.79), 114 patients with CRT, and 384 cases receiving TURBT monotherapy (ICD-9-CM codes 57.4 and 57.49).
Quality of life was determined by the frequency and duration of rehospitalizations after initial management. Survival rates were calculated as the time from the initial diagnosis of UCB to the date of last contact or death. The KaplaneMeier method 12 was used to calculate survival distributions, and all data analyses were performed using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was considered to indicate statistical significance.
Results
Of the 160 patients enrolled in this study, 122 were men, and the median age was 74.0 years. The Eastern Cooperative Oncology Group (ECOG) performance scores were 0 for 12 of the 160 patients, 1 for 87 patients, 2 for 45 patients, 3 for 15 patients, and 4 for one patient. The clinical T stage of UCB was T2 for 96 patients, T3 for 30 patients, and T4 for 34 patients. One-hundred and thirty-one patients were initially clinically N0, and 19 patients had visceral metastasis at the initial diagnosis. Forty-two patients received RC, 60 patients CRT, and 58 patients TURBT monotherapy (Table 1) .
Of the 160 patients, 113 patients had died by the time of analysis, and the mean overall survival interval was 31.5 ± 3.2 months, including 38.5 ± 3.6 months with RC, 26.2 ± 2.2 months with CRT, and 31.8 ± 3.3 months with TURBT monotherapy. The 2-year OS was 57.1% for the RC group, 35.0% for the CRT group, and 49.0% for the TURBT monotherapy group. The 2-year OS rate was significantly different among the three treatment modalities. Cox regression analysis showed the hazard ratios (HRs) [95% confidence intervals (CIs)] were 0.39 (0.21e0.70) and 0.63 (0.38e1.03) in RC (vs. TURBT) and CRT (vs. TURBT) after adjusting the comorbidity and confounding factors ( Figure 1A ). There were no significant differences in the 5-and 10-year OS rates among the three treatment modalities ( Table 2) .
We then divided the patients into three age groups: younger than 75 years, 76 years, and 77 years, and analyzed the differences in OS among these patient groups. The results showed that the 2-year OS rate was statistically significantly different only in the younger than 75 years group and 76 years group, and that those younger than 76 years had the largest log rank value (Table 3) . Therefore, we set 76 years as the cut-off age for the elderly population and analyzed the OS among each treatment modality. In accordance with the finding that those younger than 76 years receiving RC had a better OS than those receiving CRT and TURBT monotherapy within 2 years, there were no significant differences in OS of each survival interval among the different treatment modalities in the elderly population (older than 76 years) in our study ( Figure 1B ).
In accordance with our study results from the patients in our hospital database, the data from LHID2000 also showed that the overall advanced bladder cancer patients receiving RC had the best OS in comparison with CRT and TURBT monotherapy significantly. Cox regression analysis showed the HRs (CIs) were 0.55 (0.42e0.71) and 0.99 (0.71e1.38) in RC (vs. TURBT) and CRT (vs. TURBT) after adjusting risk factors ( Figure 1C) . Moreover, although the elderly population aged older than 76 years with RC from the LHID2000 also had a better OS than did those with CRT and TURBT monotherapy (log rank test, p ¼ 0.016; Figure 1D ), it seems that there was no significant difference in OS among the RC, CRT, and TURBT groups after a 5-year interval.
Eighty-nine patients were younger than 76 years, including 34 who received RC, 28 who received CRT, and 27 who received TURBT monotherapy. The mean survival interval was 39.5 ± 3.5 months in the RC group, 20.3 ± 2.1 months in the CRT group, and 33.2 ± 3.2 months in the TURBT monotherapy group. The OS duration was 41.9 ± 3.9 months in the RC group, 21.1 ± 2.2 months in the CRT group, and 35.3 ± 3.3 months in the TURBT monotherapy group. The 2-year OS of those younger than 76 years receiving RC was better than those of patients receiving CRT and TURBT monotherapy [RC > TURBT monotherapy, odds ratio (OR): 2.38; 95% CI: 1.30e4.33, p ¼ 0.005; CRT > TURBT monotherapy, OR: 1.66; 95% CI: 0.87e3.17, p ¼ 0.13]. As compared with the overall population, the 5-year OS rates of those younger than 76 years showed no significant differences, while those who received RC treatment had a slightly better outcome than those who received CRT treatment; and no significant differences were seen in the 10-year OS rates.
Of the 71 patients older than 76 years of age, eight received RC, 32 received CRT, and 31 received TURBT monotherapy. The mean survival interval was 34.1 ± 3.0 months in the RC group, 31.4 ± 2.2 months in the CRT group, and 30.4 ± 2.1 months in the TURBT monotherapy group. The CSS was 42.7 ± 4.2 months in the RC group, 31.0 ± 3.0 months in the CRT group, and 41.5 ± 3.5 months in the TURBT monotherapy group. In contrast to the overall patients and younger patients, in the older patients group there were no significant differences in OS among the three treatment modalities, even within each survival interval. The mean numbers of rehospitalizations were 5.1, 5.6, and 1.3, with durations of 61.75 days, 62.88 days, and 8.4 days after RC, CRT, and TURBT monotherapy, respectively (Table 4 ).
Discussion
We found that advanced UCB patients younger than 76 years receiving RC had a superior OS compared with those receiving TURBT monotherapy or CRT within an interval of 2 years. However, there were no significant differences among the three treatment modalities in OS of an interval > 2 years. Of the patients older than 76 years, TURBT monotherapy had CSS and OS rates similar to that of RC, which is the gold standard management for the loco-regional control of advanced UCB. 13 RC is effective in achieving local tumor control and may cure patients, with reported 5-year CSS rates ranging from 40% to 60%. 13, 14 Although patients with advanced UCB should therefore undergo RC, Gore et al 15 reported a marked underuse of RC, with only 21% of patients undergoing the procedure. Hollenbeck et al 16 reported that, despite relative increases in the proportion of younger-age cohorts undergoing RC during the course of the study, the proportion of those older than 80 years undergoing RC remained constantly lower, at 10e12%, suggesting that advances in surgical techniques and perioperative management have not been extended to very elderly patients.
In our study, 26.25% of the advanced UCB patients underwent RC, which is comparable to previous reports. Furthermore, 38.2% of those younger than 76 years and 11.27% of those older than 76 years received RC treatment, indicating a decreasing trend of RC among advanced UCB patients with increasing age. This may be due to the elderly patients having more comorbidities, poorer ability to recover from adverse events, and shorter life expectancy. In the current study, the 2-year OS was significantly better ( p ¼ 0.017) for patients younger than 76 years. This suggests that aggressive and extended treatment strategies should be given to patients of younger age, which was < 76 years in our study. RC had the best OS within 2 years of the three modalities (RC > CRT > TURBT monotherapy). In accordance with our results, Peyromaure et al 17 and Skinner et al 18 also suggested that advanced UCB patients could be considered for RC only when they had a life expectancy of at least 2 years.
Among the patients who were older than 76 years in the current study, more patients in the TURBT monotherapy group had an ECOG performance score of 1. Although there was not enough statistical power to conclude if there was a difference between the treatments, more patients were at the clinical T2 stage as compared with the CRT and RC groups (TURBT monotherapy > CRT > RC; p < 0.01). In addition, more patients had clinical N0 disease at the initial diagnosis in the TURBT monotherapy group than in the CRT and RC groups, although significant difference was not present. Based on the trend of the results of our present study, the findings agree with previous general viewpoints on the management of aged patients at high risk of perioperative morbidity and delayed recovery from aggressive surgery. However, some elderly patients with more advanced UCB, such as those with T3-and T4-stage UCB, may have been considered for aggressive RC treatment over the more conservative treatment Figure 1 . KaplaneMeier analyses of (A) comparisons of overall survival among different treatment modalities for the overall individuals of our cases, the results of which showed significant differences within the survival interval of 2 years after adjusting the comorbidity and confounding factors; (B) the elderly population (>76 years of age) from our cases, showing no statistically significant differences among the different treatment modalities; (C) comparisons of overall survival among different treatment modalities for the overall patients of LHID2000, the results of which showed significant differences among RC, CRT, and TURBT monotherapy after adjusting for risk factors; and (D) the elderly population (>76 years of age) from LHID2000, showing that differences in OS among the different treatment modalities were insignificant after a 5-year interval. CRT ¼ chemoradiotherapy; RC ¼ radical cystectomy; TURBT ¼ transurethral resection of bladder tumor. Table 2 Comparisons of 2-year, 5-year, and 10-year OS rates among the different treatment modalities of the patients overall. of TURBT monotherapy due to poor control of advanced UCB despite their poor performance status. The prognosis for advanced UCB is poor, with reported 5-year CSS and OS rates ranging from 20% to 50% regardless of the type of treatment. 6, 19 Considering the multiple comorbidities, short life expectancy, and quality of life of elderly patients, bladder-sparing treatments such as chemotherapy, radiotherapy, TURBT monotherapy, or a combination of these therapies may be considered first. Clark et al 20 reported that RC and orthotopic urinary diversion can be offered safely to carefully selected elderly patients. In the current study, the OS of those older than 76 years showed no significant difference between RC and TURBT monotherapy in different survival intervals. This suggests that the benefits of aggressive and relatively conservative treatment strategies are similar for elderly patients, and although RC can be performed in certain elderly patients, TURBT monotherapy may have an effect similar to that of RC. According to our results, we suggest that TURBT monotherapy is suitable for advanced UCB in patients older than 76 years.
Although UCB is a chemo-sensitive neoplasm, the CSS and OS rates in patients with advanced or metastatic disease are low and the prognosis is poor. 21 Even with more advanced UCB, elderly patients are significantly less likely to receive adjuvant chemotherapy. 20 Among the patients older than 76 years in the current study, 45.0% received CRT, of whom 81.2% died, with a survival interval of 31.4 months. In our elderly patients, the mortality rate was highest in the CRT group (CRT > RC > TURBT monotherapy: 81.2% > 75% > 64.3%). However, OS was not significantly different among the different treatment modalities.
Considering the quality of life of elderly patients, we analyzed the number and duration of rehospitalizations after the different treatment modalities. The mean number of rehospitalizations was highest in the CRT group and lowest in the TURBT monotherapy group. In addition, the total rehospitalization duration was longest in the CRT group and shortest in the TURBT monotherapy group. Furthermore, on the basis of similar oncological outcomes of the three treatment modalities for patients older than 76 years, the cost effectiveness of TURBT monotherapy was better than that of both RC and CRT.
Herr 22 reported that radical TURBT monotherapy for advanced UCB is an acceptable bladder-sparing treatment strategy that may produce oncological outcomes equivalent to RC in appropriately selected patients. Complete resection of the tumor is likely to be the most significant factor, and can achieve a 5-year OS rate comparable with that of RC in selected patients. 23 Recently, synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy has been shown to significantly improve loco-regional control of advanced UCB, with a reported 5-year CSS rate of 48% in one study. 6 This is in contrast to our findings, which may be due to the more advanced age of our patients with more adverse toxicity of the chemotherapy.
There are certain limitations when interpreting the findings of this study. Firstly, the retrospective assessment of advanced UCB in elderly patients may have led to comparison bias due to patient and treatment selection. Secondly, the sample size of the study was relatively small. Increasing the sample size may increases statistical power, but might require a multi-center study to obtain enough sample size. Thirdly, the enrolled patients with stage II to IV advanced UCB, patients of different treatment modalities followed individual department protocol and image study. Fourthly, any comparisons of the three treatment modalities derived from nonrandomized cohorts may result in bias, and some patients were treated with a mix of treatment modalities that may make comparison between groups to establish causality more difficult. Finally, because the database used in this study lacked a collection of certain pathologic features (such as lymphovascular invasion) and other assessment data (such as frailty, nutrition, and comorbidity), it was impossible to perform analysis controlling for those different factors. According to our results, we found patients had a better outcome when a cut-off age was set at 76 years for the selection of radical cystectomy for advanced UCB in our patient population.
